Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

about

Treating EGFR-Mutated Oncogene-Addicted Advanced Non-Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Item

http://www.wikidata.org/entity/Q58692151

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@en

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@nl

type

Item

label

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@en

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@nl

prefLabel

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@en

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@nl

P1476

Treating EGFR-Mutated Oncogene ...... : Challenges and Opportunities

@en

P2093

Elena Fountzilas

http://www.w3.org/2001/XMLSchema#string

Genovefa Polychronidou

http://www.w3.org/2001/XMLSchema#string

Giannis Mountzios

http://www.w3.org/2001/XMLSchema#string

Nikos Maniadakis

http://www.w3.org/2001/XMLSchema#string

Sofia Levva

http://www.w3.org/2001/XMLSchema#string

Vassiliki Kotoula

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidence

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Epidermal growth factor receptor mutations in lung cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JGO.18.00115

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P50

George Fountzilas

P577

2018-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30260753

http://www.w3.org/2001/XMLSchema#string

P932

6223495

http://www.w3.org/2001/XMLSchema#string